| YKL-40.com is the leading resource for comprehensive information about YKL-40, a biomarker with potential application in early diagnosis of cancer. YKL-40 has shown promise in research studies as an early diagnostic and prognostic biomarker for ovarian, colorectal and other cancers as well as rheumatoid arthritis and similar debilitating diseases. | ||
"Serum
YKL-40 is a promising new cancer marker, one with the potential to detect
cancer early in patients with the most aggressive forms of a broad spectrum
of cancer types. These are precisely the patients most likely to benefit
from initiating cancer treatment early." - Paul Price USCD |
||
|
Quidel's
Specialty Products Group is focused on delivering innovative research
and diagnostic tools with potential downstream POC applications in bone
health, oncology and related disease states. |
|
For more information visit www.quidel.com
|
| ©Copyright 2005 Quidel Corporation. All rights reserved. Quidel® and Metra® are registered trademarks of Quidel Corporation. |